Can Botulinum Toxin A Still Have a Role in Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Through Inhibition of Chronic Prostatic Inflammation?
Abstract
1. Introduction
2. Ambiguous Mechanisms of LUTS Related to BPH
3. Mechanism of BPH Related to BOO
4. Mechanism of BPH-Imbalance of Internal Hormones
5. Mechanism of BPH-Chronic Inflammation
6. Etiology of Prostatic Inflammation
7. Anti-Inflammatory Effects of Botulinum Toxin A (BoNT-A)
8. Clinical Perspectives
9. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Gravas, S.; Cornu, J.N.; Drake, M.J.; Gacci, M.; Gratzke, C.; Herrmann, T.R.W.; Mamoulakis, C.; Rieken, M.; Speakman, M.J.; Tikkinen, K.A.O.; et al. Management of Non-Neurogenic Male LUTS. Available online: https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/ (accessed on 1 January 2019).
- Foster, H.E.; Barry, M.J.; Gandhi, M.C.; Kaplan, S.A.; Kohler, T.S.; Lerner, L.B.; Lightner, D.J.; Parsons, J.K.; Roehrborn, C.G.; Welliver, C.; et al. Benign Prostatic Hyperplasia: Surgical Management of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms (2018, Amended 2019). Available online: https://www.auanet.org/guidelines/benign-prostatic-hyperplasia- (accessed on 1 January 2019).
- Abrams, P.; Cardozo, L.; Fall, M.; Griffiths, D.; Rosier, P.; Ulmsten, U.; van Kerrebroeck, P.; Victor, A.; Wein, A. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Am. J. Obstet. Gynecol. 2002, 187, 116–126. [Google Scholar] [CrossRef] [PubMed]
- Chapple, C.R.; Wein, A.J.; Abrams, P.; Dmochowski, R.R.; Giuliano, F.; Kaplan, S.A.; McVary, K.T.; Roehrborn, C.G. Lower urinary tract symptoms revisited: A broader clinical perspective. Eur. Urol. 2008, 54, 563–569. [Google Scholar] [CrossRef]
- Chapple, C.; Castro-Diaz, D.; Chuang, Y.C.; Lee, K.S.; Liao, L.; Liu, S.P.; Wang, J.; Yoo, T.K.; Chu, R.; Sumarsono, B. Prevalence of lower urinary tract symptoms in China, Taiwan, and South Korea: Results from a cross-sectional, population-based study. Adv. Ther. 2017, 34, 1953–1965. [Google Scholar] [CrossRef] [PubMed]
- Ponholzer, A.; Temml, C.; Wehrberger, C.; Marszalek, M.; Madersbacher, S. The association between vascular risk factors and lower urinary tract symptoms in both sexes. Eur. Urol. 2006, 50, 581–586. [Google Scholar] [CrossRef] [PubMed]
- Pinggera, G.M.; Mitterberger, M.; Steiner, E.; Pallwein, L.; Frauscher, F.; Aigner, F.; Bartsch, G.; Strasser, H. Association of lower urinary tract symptoms and chronic ischaemia of the lower urinary tract in elderly women and men: Assessment using colour Doppler ultrasonography. BJU Int. 2008, 102, 470–474. [Google Scholar] [CrossRef] [PubMed]
- Azadzoi, K.M.; Pontari, M.; Vlachiotis, J.; Siroky, M.B. Canine bladder blood flow and oxygenation: Changes induced by filling, contraction and outlet obstruction. J. Urol. 1996, 155, 1459–1465. [Google Scholar] [CrossRef]
- Greenland, J.E.; Brading, A.F. The effect of bladder outflow obstruction on detrusor blood flow changes during the voiding cycle in conscious pigs. J. Urol. 2001, 165, 245–248. [Google Scholar] [CrossRef] [PubMed]
- Gosling, J.A.; Gilpin, S.A.; Dixon, J.S.; Gilpin, C.J. Decrease in the autonomic innervation of human detrusor muscle in outflow obstruction. J. Urol. 1986, 136, 501–504. [Google Scholar] [CrossRef]
- Koritsiadis, G.; Stravodimos, K.; Koutalellis, G.; Agrogiannis, G.; Koritsiadis, S.; Lazaris, A.; Constantinides, C. Immunohistochemical estimation of hypoxia in human obstructed bladder and correlation with clinical variables. BJU Int. 2008, 102, 328–332. [Google Scholar] [CrossRef]
- Speakman, M.J.; Brading, A.F.; Gilpin, C.J.; Dixon, J.S.; Gilpin, S.A.; Gosling, J.A. Bladder outflow obstruction—A cause of denervation supersensitivity. J. Urol. 1987, 138, 1461–1466. [Google Scholar] [CrossRef]
- Seki, N.; Karim, O.M.; Mostwin, J.L. The effect of experimental urethral obstruction and its reversal on changes in passive electrical properties of detrusor muscle. J. Urol. 1992, 148, 1957–1961. [Google Scholar] [CrossRef]
- Greenland, J.E.; Hvistendahl, J.J.; Andersen, H.; Jorgensen, T.M.; McMurray, G.; Cortina-Borja, M.; Brading, A.F.; Frokiaer, J. The effect of bladder outlet obstruction on tissue oxygen tension and blood flow in the pig bladder. BJU Int. 2000, 85, 1109–1114. [Google Scholar] [CrossRef] [PubMed]
- Steers, W.D.; Ciambotti, J.; Etzel, B.; Erdman, S.; de Groat, W.C. Alterations in afferent pathways from the urinary bladder of the rat in response to partial urethral obstruction. J. Comp. Neurol. 1991, 310, 401–410. [Google Scholar] [CrossRef] [PubMed]
- Harrison, S.C.; Hunnam, G.R.; Farman, P.; Ferguson, D.R.; Doyle, P.T. Bladder instability and denervation in patients with bladder outflow obstruction. Br. J. Urol. 1987, 60, 519–522. [Google Scholar] [CrossRef] [PubMed]
- Komninos, C.; Mitsogiannis, I. Obstruction-induced alterations within the urinary bladder and their role in the pathophysiology of lower urinary tract symptomatology. Can. Urol. Assoc. J. 2014, 8, E524–E530. [Google Scholar] [CrossRef]
- Nickel, J.C.; Downey, J.; Hunter, D.; Clark, J. Prevalence of prostatitis-like symptoms in a population based study using the National Institutes of Health chronic prostatitis symptom index. J. Urol. 2001, 165, 842–845. [Google Scholar] [CrossRef]
- Ficarra, V.; Rossanese, M.; Zazzara, M.; Giannarini, G.; Abbinante, M.; Bartoletti, R.; Mirone, V.; Scaglione, F. The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy. Curr. Urol. Rep. 2014, 15, 463. [Google Scholar] [CrossRef]
- He, Q.; Wang, Z.; Liu, G.; Daneshgari, F.; MacLennan, G.T.; Gupta, S. Metabolic syndrome, inflammation and lower urinary tract symptoms: Possible translational links. Prostate Cancer Prostatic Dis. 2016, 19, 7–13. [Google Scholar] [CrossRef]
- Lepor, H. The pathophysiology of lower urinary tract symptoms in the ageing male population. Br. J. Urol. 1998, 81 (Suppl. S1), 29–33. [Google Scholar] [CrossRef]
- Tai, H.C.; Chung, S.D.; Ho, C.H.; Tai, T.Y.; Yang, W.S.; Tseng, C.H.; Wu, H.P.; Yu, H.J. Metabolic syndrome components worsen lower urinary tract symptoms in women with type 2 diabetes. J. Clin. Endocrinol. Metab. 2010, 95, 1143–1150. [Google Scholar] [CrossRef]
- Soler, R.; Andersson, K.E.; Chancellor, M.B.; Chapple, C.R.; de Groat, W.C.; Drake, M.J.; Gratzke, C.; Lee, R.; Cruz, F. Future direction in pharmacotherapy for non-neurogenic male lower urinary tract symptoms. Eur. Urol. 2013, 64, 610–621. [Google Scholar] [CrossRef] [PubMed]
- Kuei, C.H.; Liao, C.H.; Chiang, B.J. Significant intravesical prostatic protrusion and prostatic calcification predict unfavorable outcomes of medical treatment for male lower urinary tract symptoms. Urol. Sci. 2016, 27, 13–16. [Google Scholar] [CrossRef]
- Auffenberg, G.B.; Helfand, B.T.; McVary, K.T. Established medical therapy for benign prostatic hyperplasia. Urol. Clin. N. Am. 2009, 36, 443–459. [Google Scholar] [CrossRef] [PubMed]
- McNeal, J. Pathology of benign prostatic hyperplasia. Insight into etiology. Urol. Clin. N. Am. 1990, 17, 477–486. [Google Scholar]
- Rohr, H.P.; Bartsch, G. Human benign prostatic hyperplasia: A stromal disease? New perspectives by quantitative morphology. Urology 1980, 16, 625–633. [Google Scholar] [CrossRef]
- Franks, L.M. Benign nodular hyperplasia of the prostate; A review. Ann. R. Coll. Surg. Engl. 1953, 14, 92–106. [Google Scholar]
- McConnell, J.D. Androgen ablation and blockade in the treatment of benign prostatic hyperplasia. Urol. Clin. N. Am. 1990, 17, 661–670. [Google Scholar]
- Liao, C.H.; Li, H.Y.; Chung, S.D.; Chiang, H.S.; Yu, H.J. Significant association between serum dihydrotestosterone level and prostate volume among Taiwanese men aged 40–79 years. Aging Male 2012, 15, 28–33. [Google Scholar] [CrossRef]
- McConnell, J.D. The pathophysiology of benign prostatic hyperplasia. J. Androl. 1991, 12, 356–363. [Google Scholar]
- Harris, M.T.; Feldberg, R.S.; Lau, K.M.; Lazarus, N.H.; Cochrane, D.E. Expression of proinflammatory genes during estrogen-induced inflammation of the rat prostate. Prostate 2000, 44, 19–25. [Google Scholar] [CrossRef]
- Zhu, Y.S.; Sun, G.H. 5α-reductase isozymes in the prostate. J. Med Sci. (Taipei Taiwan) 2005, 25, 1–12. [Google Scholar]
- Nickel, J.C.; Downey, J.; Pontari, M.A.; Shoskes, D.A.; Zeitlin, S.I. A randomized placebo-controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis). BJU Int. 2004, 93, 991–995. [Google Scholar] [CrossRef] [PubMed]
- Kramer, G.; Mitteregger, D.; Marberger, M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur. Urol. 2007, 51, 1202–1216. [Google Scholar] [CrossRef] [PubMed]
- Nickel, J.C. Inflammation and benign prostatic hyperplasia. Urol. Clin. N. Am. 2008, 35, 109–115. [Google Scholar] [CrossRef] [PubMed]
- Sreenivasulu, K.; Nandeesha, H.; Dorairajan, L.N.; Rajappa, M.; Vinayagam, V. Elevated insulin and reduced insulin like growth factor binding protein-3/prostate specific antigen ratio with increase in prostate size in Benign Prostatic Hyperplasia. Clin. Chim. Acta 2017, 469, 37–41. [Google Scholar] [CrossRef] [PubMed]
- Mosli, H.H.; Esmat, A.; Atawia, R.T.; Shoieb, S.M.; Mosli, H.A.; Abdel-Naim, A.B. Metformin attenuates testosterone-induced prostatic hyperplasia in rats: A pharmacological perspective. Sci. Rep. 2015, 5, 15639. [Google Scholar] [CrossRef] [PubMed]
- Carvalho-Dias, E.; Miranda, A.; Martinho, O.; Mota, P.; Costa, A.; Nogueira-Silva, C.; Moura, R.S.; Alenina, N. Serotonin regulates prostate growth through androgen receptor modulation. Sci. Rep. 2017, 7, 15428. [Google Scholar] [CrossRef] [PubMed]
- Sutcliffe, S.; Giovannucci, E.; De Marzo, A.M.; Willett, W.C.; Platz, E.A. Sexually transmitted infections, prostatitis, ejaculation frequency, and the odds of lower urinary tract symptoms. Am. J. Epidemiol. 2005, 162, 898–906. [Google Scholar] [CrossRef] [PubMed]
- Nickel, J.C. Prostatic inflammation in benign prostatic hyperplasia—The third component? Can. J. Urol. 1994, 1, 1–4. [Google Scholar] [PubMed]
- Nickel, J.C.; Roehrborn, C.G.; O’Leary, M.P.; Bostwick, D.G.; Somerville, M.C.; Rittmaster, R.S. The relationship between prostate inflammation and lower urinary tract symptoms: Examination of baseline data from the REDUCE trial. Eur. Urol. 2008, 54, 1379–1384. [Google Scholar] [CrossRef] [PubMed]
- St Sauver, J.L.; Jacobson, D.J.; McGree, M.E.; Lieber, M.M.; Jacobsen, S.J. Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia. Am. J. Epidemiol. 2006, 164, 760–768. [Google Scholar] [CrossRef] [PubMed]
- Castro, P.; Xia, C.; Gomez, L.; Lamb, D.J.; Ittmann, M. Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia. Prostate 2004, 60, 153–159. [Google Scholar] [CrossRef] [PubMed]
- Penna, G.; Mondaini, N.; Amuchastegui, S.; Degli Innocenti, S.; Carini, M.; Giubilei, G.; Fibbi, B.; Colli, E.; Maggi, M.; Adorini, L. Seminal plasma cytokines and chemokines in prostate inflammation: Interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur. Urol. 2007, 51, 524–533. [Google Scholar] [CrossRef] [PubMed]
- Schauer, I.G.; Ressler, S.J.; Tuxhorn, J.A.; Dang, T.D.; Rowley, D.R. Elevated epithelial expression of interleukin-8 correlates with myofibroblast reactive stroma in benign prostatic hyperplasia. Urology 2008, 72, 205–213. [Google Scholar] [CrossRef] [PubMed]
- Penna, G.; Fibbi, B.; Amuchastegui, S.; Cossetti, C.; Aquilano, F.; Laverny, G.; Gacci, M.; Crescioli, C.; Maggi, M.; Adorini, L. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J. Immunol. 2009, 182, 4056–4064. [Google Scholar] [CrossRef] [PubMed]
- Fibbi, B.; Penna, G.; Morelli, A.; Adorini, L.; Maggi, M. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int. J. Androl. 2010, 33, 475–488. [Google Scholar] [CrossRef] [PubMed]
- Sciarra, A.; Di Silverio, F.; Salciccia, S.; Autran Gomez, A.M.; Gentilucci, A.; Gentile, V. Inflammation and chronic prostatic diseases: Evidence for a link? Eur. Urol. 2007, 52, 964–972. [Google Scholar] [CrossRef] [PubMed]
- Penna, G.; Fibbi, B.; Amuchastegui, S.; Corsiero, E.; Laverny, G.; Silvestrini, E.; Chavalmane, A.; Morelli, A.; Sarchielli, E.; Vannelli, G.B.; et al. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. Prostate 2009, 69, 480–493. [Google Scholar] [CrossRef] [PubMed]
- Krieger, J.N.; Lee, S.W.; Jeon, J.; Cheah, P.Y.; Liong, M.L.; Riley, D.E. Epidemiology of prostatitis. Int. J. Antimicrob. Agents 2008, 31 (Suppl. S1), S85–S90. [Google Scholar] [CrossRef] [PubMed]
- Whitmore, W.F.; Gittes, R.F. Studies on the prostate and testis as immunologically privileged sites. Cancer Treat. Rep. 1977, 61, 217–222. [Google Scholar] [PubMed]
- Zisman, A.; Zisman, E.; Lindner, A.; Velikanov, S.; Siegel, Y.I.; Mozes, E. Autoantibodies to prostate specific antigen in patients with benign prostatic hyperplasia. J. Urol. 1995, 154, 1052–1055. [Google Scholar] [CrossRef]
- Motrich, R.D.; Maccioni, M.; Molina, R.; Tissera, A.; Olmedo, J.; Riera, C.M.; Rivero, V.E. Presence of INFγ-secreting lymphocytes specific to prostate antigens in a group of chronic prostatitis patients. Clin. Immunol. 2005, 116, 149–157. [Google Scholar] [CrossRef] [PubMed]
- Ponniah, S.; Arah, I.; Alexander, R.B. PSA is a candidate self-antigen in autoimmune chronic prostatitis/chronic pelvic pain syndrome. Prostate 2000, 44, 49–54. [Google Scholar] [CrossRef]
- Miller, L.J.; Fischer, K.A.; Goralnick, S.J.; Litt, M.; Burleson, J.A.; Albertsen, P.; Kreutzer, D.L. Nerve growth factor and chronic prostatitis/chronic pelvic pain syndrome. Urology 2002, 59, 603–608. [Google Scholar] [CrossRef]
- Varilek, G.W.; Weinstock, J.V.; Pantazis, N.J. Isolated hepatic granulomas from mice infected with Schistosoma mansoni contain nerve growth factor. Infect. Immun. 1991, 59, 4443–4449. [Google Scholar] [PubMed]
- Mazurek, N.; Weskamp, G.; Erne, P.; Otten, U. Nerve growth factor induces mast cell degranulation without changing intracellular calcium levels. FEBS Lett. 1986, 198, 315–320. [Google Scholar] [CrossRef]
- Ou, Z.; He, Y.; Qi, L.; Zu, X.; Wu, L.; Cao, Z.; Li, Y.; Liu, L.; Dube, D.A.; Wang, Z.; et al. Infiltrating mast cells enhance benign prostatic hyperplasia through IL-6/STAT3/Cyclin D1 signals. Oncotarget 2017, 8, 59156–59164. [Google Scholar] [CrossRef] [PubMed]
- Lindsay, R.M.; Harmar, A.J. Nerve growth factor regulates expression of neuropeptide genes in adult sensory neurons. Nature 1989, 337, 362–364. [Google Scholar] [CrossRef] [PubMed]
- Chien, C.-T.; Yu, H.-J.; Lin, T.-B.; Lai, M.-K.; Hsu, S.-M. Substance P via NK1 receptor facilitates hyperactive bladder afferent signaling via action of ROS. Am. J. Physiol. Ren. Physiol. 2003, 284, F840–F851. [Google Scholar] [CrossRef]
- Funahashi, Y.; Takahashi, R.; Mizoguchi, S.; Suzuki, T.; Takaoka, E.; Ni, J.; Wang, Z.; DeFranco, D.B.; de Groat, W.C.; Tyagi, P. Bladder overactivity and afferent hyperexcitability induced by prostate-to-bladder cross-sensitization in rats with prostatic inflammation. J. Physiol. 2019, 597, 2063–2078. [Google Scholar] [CrossRef]
- Vital, P.; Castro, P.; Ittmann, M. Oxidative stress promotes benign prostatic hyperplasia. Prostate 2016, 76, 58–67. [Google Scholar] [CrossRef] [PubMed]
- Chiang, B.J.; Chen, T.W.; Chung, S.D.; Lee, W.Z.; Chien, C.T. Synthetic nickel-containing superoxide dismutase attenuates para-phenylenediamine-induced bladder dysfunction in rats. Oncotarget 2017, 8, 105735–105748. [Google Scholar] [CrossRef] [PubMed]
- Dearakhshandeh, N.; Mogheiseh, A. Changes in the oxidative stress factors and inflammatory proteins following the treatment of BPH-induced dogs with an anti-proliferative agent called tadalafil. J. Vet. Pharmacol. Ther. 2019. [Google Scholar] [CrossRef] [PubMed]
- Sugar, L.M. Inflammation and prostate cancer. Can. J. Urol. 2006, 13 (Suppl. S1), 46–47. [Google Scholar] [PubMed]
- Di Silverio, F.; Gentile, V.; De Matteis, A.; Mariotti, G.; Giuseppe, V.; Luigi, P.A.; Sciarra, A. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: A retrospective analysis. Eur. Urol. 2003, 43, 164–175. [Google Scholar] [CrossRef]
- McVary, K.T.; Rademaker, A.; Lloyd, G.L.; Gann, P. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J. Urol. 2005, 174, 1327–1433. [Google Scholar] [CrossRef] [PubMed]
- Kim, J.; Yanagihara, Y.; Kikugawa, T.; Ji, M.; Tanji, N.; Masayoshi, Y.; Freeman, M.R. A signaling network in phenylephrine-induced benign prostatic hyperplasia. Endocrinology 2009, 150, 3576–3583. [Google Scholar] [CrossRef] [PubMed]
- Kanagawa, K.; Sugimura, K.; Kuratsukuri, K.; Ikemoto, S.; Kishimoto, T.; Nakatani, T. Norepinephrine activates P44 and P42 MAPK in human prostate stromal and smooth muscle cells but not in epithelial cells. Prostate 2003, 56, 313–318. [Google Scholar] [CrossRef] [PubMed]
- Huang, X.; Lee, C. Regulation of stromal proliferation, growth arrest, differentiation and apoptosis in benign prostatic hyperplasia by TGF-beta. Front. Biosci. 2003, 8, s740–s749. [Google Scholar]
- Turton, K.; Chaddock, J.A.; Acharya, K.R. Botulinum and tetanus neurotoxins: Structure, function and therapeutic utility. Trends Biochem. Sci. 2002, 27, 552–558. [Google Scholar] [CrossRef]
- Chuang, Y.C.; Huang, C.C.; Kang, H.Y.; Chiang, P.H.; Demiguel, F.; Yoshimura, N.; Chancellor, M.B. Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland. J. Urol. 2006, 175, 1158–1163. [Google Scholar] [CrossRef]
- Lin, A.T.; Yang, A.H.; Chen, K.K. Effects of botulinum toxin A on the contractile function of dog prostate. Eur. Urol. 2007, 52, 582–589. [Google Scholar] [CrossRef] [PubMed]
- Chuang, Y.C.; Tu, C.H.; Huang, C.C.; Lin, H.J.; Chiang, P.H.; Yoshimura, N.; Chancellor, M.B. Intraprostatic injection of botulinum toxin type-A relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs. BMC Urol. 2006, 6, 12. [Google Scholar] [CrossRef] [PubMed]
- Chuang, Y.C.; Chiang, P.H.; Yoshimura, N.; De Miguel, F.; Chancellor, M.B. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int. 2006, 98, 1033–1037. [Google Scholar] [CrossRef] [PubMed]
- Borodic, G.E.; Acquadro, M.; Johnson, E.A. Botulinum toxin therapy for pain and inflammatory disorders: Mechanisms and therapeutic effects. Expert Opin. Investig. Drugs 2001, 10, 1531–1544. [Google Scholar] [CrossRef] [PubMed]
- Yoo, K.Y.; Lee, H.S.; Cho, Y.K.; Lim, Y.S.; Kim, Y.S.; Koo, J.H.; Yoon, S.J.; Lee, J.H.; Jang, K.H.; Song, S.H. Anti-inflammatory effects of botulinum toxin type A in a complete Freund’s adjuvant-induced arthritic knee joint of hind leg on rat model. Neurotox. Res. 2014, 26, 32–39. [Google Scholar] [CrossRef] [PubMed]
- Choi, J.E.; Werbel, T.; Wang, Z.; Wu, C.C.; Yaksh, T.L.; Di Nardo, A. Botulinum toxin blocks mast cells and prevents rosacea like inflammation. J. Dermatol. Sci. 2019, 93, 58–64. [Google Scholar] [CrossRef] [PubMed]
- Liu, H.T.; Kuo, H.C. Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. Urology 2007, 70, 463–468. [Google Scholar] [CrossRef]
- Chuang, Y.C.; Yoshimura, N.; Huang, C.C.; Chiang, P.H.; Chancellor, M.B. Intravesical botulinum toxin A administration produces analgesia against acetic acid induced bladder pain responses in rats. J. Urol. 2004, 172, 1529–1532. [Google Scholar] [CrossRef]
- Aoki, K.R. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005, 26, 785–793. [Google Scholar] [CrossRef]
- Chuang, Y.C.; Yoshimura, N.; Huang, C.C.; Wu, M.; Chiang, P.H.; Chancellor, M.B. Intraprostatic botulinum toxin A injection inhibits cyclooxygenase-2 expression and suppresses prostatic pain on capsaicin induced prostatitis model in rat. J. Urol. 2008, 180, 742–748. [Google Scholar] [CrossRef]
- Uchiyama, A.; Yamada, K.; Perera, B.; Ogino, S.; Yokoyama, Y.; Takeuchi, Y.; Ishikawa, O.; Motegi, S. Protective effect of botulinum toxin A after cutaneous ischemia-reperfusion injury. Sci. Rep. 2015, 5, 9072. [Google Scholar] [CrossRef]
- Schraufstatter, I.U.; Chung, J.; Burger, M. IL-8 activates endothelial cell CXCR1 and CXCR2 through Rho and Rac signaling pathways. Am. J. Physiol. Lung Cell. Mol. Physiol. 2001, 280, L1094–L1103. [Google Scholar] [CrossRef]
- Kuo, H.C. Prostate botulinum A toxin injection—An alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 2005, 65, 670–674. [Google Scholar] [CrossRef]
- Silva, J.; Pinto, R.; Carvalho, T.; Botelho, F.; Silva, P.; Oliveira, R.; Silva, C.; Cruz, F.; Dinis, P. Intraprostatic botulinum toxin type A injection in patients with benign prostatic enlargement: Duration of the effect of a single treatment. BMC Urol. 2009, 9, 9. [Google Scholar] [CrossRef]
- Maria, G.; Brisinda, G.; Civello, I.M.; Bentivoglio, A.R.; Sganga, G.; Albanese, A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: Results of a randomized, placebo-controlled study. Urology 2003, 62, 259–264. [Google Scholar] [CrossRef]
- Chuang, Y.C.; Chiang, P.H.; Huang, C.C.; Yoshimura, N.; Chancellor, M.B. Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology 2005, 66, 775–779. [Google Scholar] [CrossRef]
- Brisinda, G.; Cadeddu, F.; Vanella, S.; Mazzeo, P.; Marniga, G.; Maria, G. Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: Early and long-term results. Urology 2009, 73, 90–94. [Google Scholar] [CrossRef]
- McVary, K.T.; Roehrborn, C.G.; Chartier-Kastler, E.; Efros, M.; Bugarin, D.; Chen, R.; Patel, A.; Haag-Molkenteller, C. A multicenter, randomized, double-blind, placebo controlled study of onabotulinumtoxinA 200 U to treat lower urinary tract symptoms in men with benign prostatic hyperplasia. J. Urol. 2014, 192, 150–156. [Google Scholar] [CrossRef]
- Marberger, M.; Chartier-Kastler, E.; Egerdie, B.; Lee, K.S.; Grosse, J.; Bugarin, D.; Zhou, J.; Patel, A.; Haag-Molkenteller, C. A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. Eur. Urol. 2013, 63, 496–503. [Google Scholar] [CrossRef]
- Shim, S.R.; Cho, Y.J.; Shin, I.S.; Kim, J.H. Efficacy and safety of botulinum toxin injection for benign prostatic hyperplasia: A systematic review and meta-analysis. Int. Urol. Nephrol. 2016, 48, 19–30. [Google Scholar] [CrossRef]
- Marchal, C.; Perez, J.E.; Herrera, B.; Machuca, F.J.; Redondo, M. The use of botulinum toxin in benign prostatic hyperplasia. Neurourol. Urodyn. 2012, 31, 86–92. [Google Scholar] [CrossRef]
- Mangera, A.; Apostolidis, A.; Andersson, K.E.; Dasgupta, P.; Giannantoni, A.; Roehrborn, C.; Novara, G.; Chapple, C. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Eur. Urol. 2014, 65, 981–990. [Google Scholar] [CrossRef]
- Mangera, A.; Andersson, K.E.; Apostolidis, A.; Chapple, C.; Dasgupta, P.; Giannantoni, A.; Gravas, S.; Madersbacher, S. Contemporary management of lower urinary tract disease with botulinum toxin A: A systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur. Urol. 2011, 60, 784–795. [Google Scholar] [CrossRef]
- El-Enen, M.A.; Abou-Farha, M.; El-Abd, A.; El-Tatawy, H.; Tawfik, A.; El-Abd, S.; Rashed, M.; El-Sharaby, M. Intraprostatic injection of botulinum toxin-A in patients with refractory chronic pelvic pain syndrome: The transurethral vs. transrectal approach. Arab J. Urol. 2015, 13, 94–99. [Google Scholar] [CrossRef]
- Falahatkar, S.; Shahab, E.; Gholamjani Moghaddam, K.; Kazemnezhad, E. Transurethral intraprostatic injection of botulinum neurotoxin type A for the treatment of chronic prostatitis/chronic pelvic pain syndrome: Results of a prospective pilot double-blind and randomized placebo-controlled study. BJU Int. 2015, 116, 641–649. [Google Scholar] [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Chiang, B.-J.; Kuo, H.-C.; Liao, C.-H. Can Botulinum Toxin A Still Have a Role in Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Through Inhibition of Chronic Prostatic Inflammation? Toxins 2019, 11, 547. https://doi.org/10.3390/toxins11090547
Chiang B-J, Kuo H-C, Liao C-H. Can Botulinum Toxin A Still Have a Role in Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Through Inhibition of Chronic Prostatic Inflammation? Toxins. 2019; 11(9):547. https://doi.org/10.3390/toxins11090547
Chicago/Turabian StyleChiang, Bing-Juin, Hann-Chorng Kuo, and Chun-Hou Liao. 2019. "Can Botulinum Toxin A Still Have a Role in Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Through Inhibition of Chronic Prostatic Inflammation?" Toxins 11, no. 9: 547. https://doi.org/10.3390/toxins11090547
APA StyleChiang, B.-J., Kuo, H.-C., & Liao, C.-H. (2019). Can Botulinum Toxin A Still Have a Role in Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Through Inhibition of Chronic Prostatic Inflammation? Toxins, 11(9), 547. https://doi.org/10.3390/toxins11090547